Review



soluble intercellular adhesion molecule 1 sicam 1  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems soluble intercellular adhesion molecule 1 sicam 1
    Soluble Intercellular Adhesion Molecule 1 Sicam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 60 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/soluble intercellular adhesion molecule 1 sicam 1/product/R&D Systems
    Average 93 stars, based on 60 article reviews
    soluble intercellular adhesion molecule 1 sicam 1 - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    soluble intercellular adhesion molecule 1 sicam 1  (R&D Systems)
    93
    R&D Systems soluble intercellular adhesion molecule 1 sicam 1
    Soluble Intercellular Adhesion Molecule 1 Sicam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/soluble intercellular adhesion molecule 1 sicam 1/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    soluble intercellular adhesion molecule 1 sicam 1 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    icam 1 by cdim00 vcam 1 by dvc00 and e selectin by pdsle00 minneapolis mn  (R&D Systems)
    93
    R&D Systems icam 1 by cdim00 vcam 1 by dvc00 and e selectin by pdsle00 minneapolis mn
    Odds ratios and 95% CIs for incident CKD per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as <t>follows:</t> <t>ICAM-1,</t> 0.25 <t>ln(ng/ml);</t> <t>VCAM-1,</t> 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease defined by eGFR <60 ml/min per 1.73 m 2 plus 40% decline from baseline or new kidney failure; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.
    Icam 1 By Cdim00 Vcam 1 By Dvc00 And E Selectin By Pdsle00 Minneapolis Mn, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/icam 1 by cdim00 vcam 1 by dvc00 and e selectin by pdsle00 minneapolis mn/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    icam 1 by cdim00 vcam 1 by dvc00 and e selectin by pdsle00 minneapolis mn - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    human icam1 quantikine elisa kit  (R&D Systems)
    94
    R&D Systems human icam1 quantikine elisa kit
    Odds ratios and 95% CIs for incident CKD per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as <t>follows:</t> <t>ICAM-1,</t> 0.25 <t>ln(ng/ml);</t> <t>VCAM-1,</t> 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease defined by eGFR <60 ml/min per 1.73 m 2 plus 40% decline from baseline or new kidney failure; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.
    Human Icam1 Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human icam1 quantikine elisa kit/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    human icam1 quantikine elisa kit - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    human icam 1 quantikine elisa  (R&D Systems)
    99
    R&D Systems human icam 1 quantikine elisa
    Odds ratios and 95% CIs for incident CKD per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as <t>follows:</t> <t>ICAM-1,</t> 0.25 <t>ln(ng/ml);</t> <t>VCAM-1,</t> 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease defined by eGFR <60 ml/min per 1.73 m 2 plus 40% decline from baseline or new kidney failure; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.
    Human Icam 1 Quantikine Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human icam 1 quantikine elisa/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    human icam 1 quantikine elisa - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    human icam 1 cd54 allele specific immunoassay kit  (R&D Systems)
    94
    R&D Systems human icam 1 cd54 allele specific immunoassay kit
    Odds ratios and 95% CIs for incident CKD per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as <t>follows:</t> <t>ICAM-1,</t> 0.25 <t>ln(ng/ml);</t> <t>VCAM-1,</t> 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease defined by eGFR <60 ml/min per 1.73 m 2 plus 40% decline from baseline or new kidney failure; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.
    Human Icam 1 Cd54 Allele Specific Immunoassay Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human icam 1 cd54 allele specific immunoassay kit/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    human icam 1 cd54 allele specific immunoassay kit - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    scd40l  (R&D Systems)
    94
    R&D Systems scd40l
    Odds ratios and 95% CIs for incident CKD per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as <t>follows:</t> <t>ICAM-1,</t> 0.25 <t>ln(ng/ml);</t> <t>VCAM-1,</t> 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease defined by eGFR <60 ml/min per 1.73 m 2 plus 40% decline from baseline or new kidney failure; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.
    Scd40l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scd40l/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    scd40l - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    elisa kits  (R&D Systems)
    94
    R&D Systems elisa kits
    Odds ratios and 95% CIs for incident CKD per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as <t>follows:</t> <t>ICAM-1,</t> 0.25 <t>ln(ng/ml);</t> <t>VCAM-1,</t> 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease defined by eGFR <60 ml/min per 1.73 m 2 plus 40% decline from baseline or new kidney failure; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.
    Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elisa kits/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    elisa kits - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Odds ratios and 95% CIs for incident CKD per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as follows: ICAM-1, 0.25 ln(ng/ml); VCAM-1, 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease defined by eGFR <60 ml/min per 1.73 m 2 plus 40% decline from baseline or new kidney failure; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.

    Journal: Kidney International Reports

    Article Title: Endothelial Dysfunction Biomarkers and CKD Incidence in the REGARDS Cohort

    doi: 10.1016/j.ekir.2024.04.056

    Figure Lengend Snippet: Odds ratios and 95% CIs for incident CKD per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as follows: ICAM-1, 0.25 ln(ng/ml); VCAM-1, 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease defined by eGFR <60 ml/min per 1.73 m 2 plus 40% decline from baseline or new kidney failure; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.

    Article Snippet: Each biomarker was measured using commercially available enzyme-linked immunoassays: FVIII antigen by Affinity Biologicals (F8C-Elisa; Hamilton, Ontario, Canada) and the remainder by R&D Systems (ICAM-1 by CDIM00, VCAM-1 by DVC00, and E-selectin by PDSLE00; Minneapolis, MN).

    Techniques: Transformation Assay, Filtration

    Odds ratios and 95% CIs for incident ≥ 30% decline in eGFR per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as follows: ICAM-1, 0.25 ln(ng/ml); VCAM-1, 0.36 ln(ng/ml); factor VIII, 0.32 ln(%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.

    Journal: Kidney International Reports

    Article Title: Endothelial Dysfunction Biomarkers and CKD Incidence in the REGARDS Cohort

    doi: 10.1016/j.ekir.2024.04.056

    Figure Lengend Snippet: Odds ratios and 95% CIs for incident ≥ 30% decline in eGFR per 1 SD increment of biomarkers of endothelial dysfunction. a Model 1 was unadjusted. b Model 2 adjusted for age, sex, race, and geographic region of residence. c Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. d Model 4 was further adjusted for baseline eGFR and ACR. 1 log-transformed SD was, as follows: ICAM-1, 0.25 ln(ng/ml); VCAM-1, 0.36 ln(ng/ml); factor VIII, 0.32 ln(%); E-selectin, 0.46 ln(ng/ml). Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.

    Article Snippet: Each biomarker was measured using commercially available enzyme-linked immunoassays: FVIII antigen by Affinity Biologicals (F8C-Elisa; Hamilton, Ontario, Canada) and the remainder by R&D Systems (ICAM-1 by CDIM00, VCAM-1 by DVC00, and E-selectin by PDSLE00; Minneapolis, MN).

    Techniques: Transformation Assay, Filtration

    Odds ratios and 95% CIs for incident albuminuria per 1 SD increment of biomarkers of endothelial dysfunction. Model 1 was unadjusted. a Model adjusted for age, sex, race, and geographic region of residence. b Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. c Model 4 was further adjusted for baseline eGFR and ACR. Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. Albuminuria was defined as ACR ≥30 mg/g. 1 log-transformed SD was, as follows: ICAM-1, 0.25 ln(ng/ml); VCAM-1, 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.

    Journal: Kidney International Reports

    Article Title: Endothelial Dysfunction Biomarkers and CKD Incidence in the REGARDS Cohort

    doi: 10.1016/j.ekir.2024.04.056

    Figure Lengend Snippet: Odds ratios and 95% CIs for incident albuminuria per 1 SD increment of biomarkers of endothelial dysfunction. Model 1 was unadjusted. a Model adjusted for age, sex, race, and geographic region of residence. b Model 3 was further adjusted for body mass index, hypertension, diabetes, coronary artery disease, smoking status, and dyslipidemia. c Model 4 was further adjusted for baseline eGFR and ACR. Regression models were weighted to reflect the entire cohort from which this subcohort was sampled. Albuminuria was defined as ACR ≥30 mg/g. 1 log-transformed SD was, as follows: ICAM-1, 0.25 ln(ng/ml); VCAM-1, 0.36 ln(ng/ml); factor VIII, 0.32 ln (%); E-selectin, 0.46 ln(ng/ml). ACR, urinary albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate by 2021 CKD-EPI equation by serum creatinine and cystatin C; ICAM-1, intercellular cellular adhesion molecule 1.

    Article Snippet: Each biomarker was measured using commercially available enzyme-linked immunoassays: FVIII antigen by Affinity Biologicals (F8C-Elisa; Hamilton, Ontario, Canada) and the remainder by R&D Systems (ICAM-1 by CDIM00, VCAM-1 by DVC00, and E-selectin by PDSLE00; Minneapolis, MN).

    Techniques: Transformation Assay, Filtration